MaxCyte, Inc. Notice of Full Year Results (5163V)
April 15 2021 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5163V
MaxCyte, Inc.
15 April 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT,
MXCL, MXCN), a leading provider of cell-engineering platform
technologies for next generation cell-based therapies, will be
announcing its financial results for the year ended 31 December
2020 on Tuesday, 20 April 2021.
Doug Doerfler, Chief Executive Officer, and Amanda Murphy, Chief
Financial Officer, will host a conference call for analysts at
14.00pm BST the day of the announcement. The presentation will be
available on the Investors section of MaxCyte's website on the day
of the meeting at
https://investors.maxcyte.com/news-events/documents-presentations .
###
For further information please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott / Chris Welsh
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies that are driving the next--generation of cell-based
therapies and making a meaningful difference for patients. The
Company's technology is employed by leading drug developers
worldwide, including all of the top ten global biopharmaceutical
companies. MaxCyte has granted 12 strategic platform licences to
leading cell-based therapy developers. Through 2020, MaxCyte has
granted licenses for more than 140 cell therapy programs, with over
100 licensed for clinical use. MaxCyte was founded in 1998 and is
headquartered in Gaithersburg, Maryland, U.S. For more information,
visit www.maxcyte.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUSORRANUSAUR
(END) Dow Jones Newswires
April 15, 2021 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024